Immix Biopharma, Inc. Common Stock
Here’s whether Immix Biopharma, Inc. Common Stock (IMMX) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Neutral.
Positives: trading above the 200-day MA (long-term uptrend intact); 50-day MA is rising (+0.22% over 10 days); RSI 37 — healthy momentum range; strong 1-year return of +205.4%. Concerns: below the 50-day MA (medium-term momentum negative); 3-month momentum negative (-13.5%). Currently 29.8% off its 52-week high. Score: +3/7.
IMMX is holding above its long-term 200-day MA ($7.26) but has slipped below the 50-day MA ($9.42), pointing to short-term weakness in an otherwise intact trend. An RSI of 37.2 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of +205.4% compares to +16.5% for SPY (beat the market by 188.9%). The current 29.8% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.